Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designal Type Company of the Un

U. S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE

ATTORNEY'S DOCKET NUMBER

ITR0053YP

TRANSMITTAL LETTER TO THE UNITED STATES

II S APPLICATION NO (If known see 37 CFR 1.5)

DESIGNATED/ELECTE CONCERNING A FILIN	ED OFFICE (DO/EO/US) IG UNDER 35 U.S.C. 371	10/582621					
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED					
PCT/EP2004/014159	December 10, 2004	December 18, 2003					
TITLE OF INVENTION	TITLE OF INVENTION						
METHOD FOR IDENTIFYING HIST	ONE DEACETYLASE INHIBITORS	5					
APPLICANT(S) FOR DO/EO/US							
Michele Pallaoro, Paola Gallinari, Ser							
Applicant herewith submits to the other information:	United States Designated/Elected Of	fice (DO/EO/US) the following items and					
1. X This is a FIRST submission	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.						
2. This is a SECOND or SUBS	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.						
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.							
4. X The US has been elected (PCT Article 31).							
5. A copy of the International Application as filed [35 U.S.C. 371(c)(2)]							
a. is attached hereto (required only if not communicated by the International Bureau).							
b. has been communicated by the International Bureau.							
c. X is not required, as the application was filed in the United States Receiving Office (RO/US).							
6. An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)]. a. is attached hereto							
	b. has been previously submitted under 35 U.S.C. 154(d)(4).						
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. a. are attached hereto (required only if not communicated by the International Bureau).							
b. have been communication	b. have been communicated by the International Bureau.						
c. have not been made; however, the time limit for making such amendments has NOT expired.							
d. have not been made a	d. have not been made and will not be made.						
8. An English language translat	An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].						
An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].							
Article 36 [35 U.S.C. 371(c)		Preliminary Examination Report under PCT					
	Statement under 37 CFR 1.97 and 1.98						
	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31						
13. A preliminary amendment.							
14. An Application Data Sheet u	An Application Data Sheet under 37 CFR 1.76.						
5. A substitute specification.							
16. A power of attorney and/or of	A power of attorney and/or change of address letter.						
A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.							
18. A second copy of the publish	A second copy of the published International Application under 35 U.S.C.154(d)(4).						
19. A second copy of the English	A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).						
20. Other items or information: Sequence Statement							

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected of the Option of Designated Elected Option of Design

U.SPAPPLICATION N	O. (If known, see 37 (CFR 1.5)	INTERN	ATIONAL APPLICATION NO.		ATTORNET'S DOC	LKEI NUMBER
	82621			ITR0053YP			
The following fees are submitted:			CALCULATIONS	PTO USE ONLY			
21. X Basic national fee\$300			\$300	\$300.00			
22. Examination fee (37 CFR 1.492(c))							
If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)\$0							
All other situations\$200							
23. X Search fee	(37 CFR 1.492(b)))					
			•	inary examination report prep	•		
IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)							
International Searching Authority\$100					\$400.00		
International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB					COT \$400		
		·			21, 22 and 23=	\$700.00	
				er over 100 sheets (excluding			
computer progra	•			The fee is \$250 for each add	itional 50 sheets of		
Total Sheets	Extra Sheets			additional 50 or fraction to a whole number)	RATE		
- 100 =	0 /50	0		0	X \$250.00	\$0.00	
Surcharge of \$130.00 priority date [37 CFF	_	oath or decla	ration la	ter than 30 months from the e	arliest claimed		
CLAIMS		ER FILED	•	NUMBER EXTRA	RATE		<u> </u>
Total Claims		21	- 20 =	1	X \$50.00	\$50.00	
Independent Claims		3	- 3 =	0	X \$200.00	\$0.00	
				0	•	\$0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$360.00				¢750.00			
TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) =			\$750.00	<u> </u>			
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)].							
TOTAL NATIONAL FEE =				\$750.00			
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).\$40.00 per property.					+		
			<u> </u>	TOTAL FEES ENCLO	SED =	\$750.00	
						Amount to be refunded:	
						Amount to be charged:	
a. A check	in the amount o	f\$		to cover the above fees is	enclosed.		
b. Please charge my Deposit Account No. 13-2755 in the amount of \$750.00 to cover the above fees.							
A duplicate copy of this sheet is enclosed. c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any							
1	overpayment to the Deposit Account No. <u>13-2755</u> . A duplicate copy of this sheet is enclosed.						
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.							
SEND ALL CORRESPONDENCE TO:							
Customer No. 000210							
····································							
MERCK & CO., INC. Patent Department, RY60-30							
P.O. Box 2000 SIGNATURE							
126 East Lincoln Avenue					\searrow		
Rahway, New Jersey 07065-0970							
NAME							
DATE: June 12			_	43.	039		
PHONE #: (73	PHONE #: (732) 594-6914 REGISTRATION NUMBER						

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/OS)Concerning a Submission Under 35 U.S.C. 371" Approved for use through 3/31/2007. OMB 0651-0021

AP3 Rec'd PCT/PTO 12 JUN 2506

Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ITR0053YP
PCT/EP2004/014159
December 10, 2004
December 18, 2003
METHOD FOR IDENTIFYING HISTONE DEACETYLASE INHIBITORS
Michele Pallaoro Paola Gallinari Sergio Altamura Christian Steinkuhler

	EXPRESS MAIL CERTIFICATE
DATE OF DE	POSIT June 12, 2006
EXPRESS MA	AIL NO. EV660606448US
	CERTIFY THAT THIS CORRESPONDENCE IS BEING
	D WITH THE UNITED STATES POSTAL SERVICE AS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE
	N ENVELOPE ADDRESSED TO COMMISSIONER FOR P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY	B. Crowley DATE JUNE 12, 200